Page 49 - Direct To ConsumerFINAL3.25

Early detection and treatment of Hepatitis B (HBV) and Hepatitis C (HCV) are crucial for improving patient outcomes and preventing the progression of liver disease.
Hepatitis B:
For individuals with chronic HBV, early detection allows for timely intervention and management, which can help prevent complications such as liver cirrhosis, liver failure, or hepatocellular carcinoma (liver cancer) (Terrault et al., 2018)1. Effective antiviral medications, such as nucleos(t)ide analogues, can suppress viral replication and decrease the risk of liver- related complications (Marcellin et al., 2013)2. In some cases, the treatment can lead to a functional cure, defined as sustained loss of Hepatitis B surface antigen (HBsAg) and undetectable viral DNA (Terrault et al., 2018)1.
Hepatitis C:
The landscape of HCV treatment has undergone a significant transformation with the advent of direct-acting antivirals (DAAs), which have revolutionized the management of the disease. Early detection and treatment with DAAs have shown to be highly effective, with cure rates exceeding 90% in most patient populations (Falade-Nwulia et al., 2017)3. Achieving a sustained virologic response (SVR), which indicates successful treatment, reduces the risk of liver cirrhosis, liver failure, hepatocellular carcinoma, and overall mortality (van der Meer et al., 2012)4.
49